Overview

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Status:
Completed

Trial end date:
2019-01-18

Target enrollment:

Participant gender:

Summary

This is an open label study designed to examine the effects of Enzalutamide with concurrent administration of Radium Ra 223 dichloride in Castrate-Resistant (Hormone-Refractory) Prostate Cancer subjects with symptomatic bone metastases in both the pre- and post-chemotherapy setting.

Phase:

Phase 2

Details

Lead Sponsor:

Carolina Research Professionals, LLC

Collaborator:

Astellas Pharma Inc

Treatments:

Hormones
Radium Ra 223 dichloride
Succinylcholine